Buy Rating Affirmed for COMPASS Pathways Amid Promising Psilocybin Treatment Prospects and Strategic Market Positioning
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
RBC Capital Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
RBC Capital analyst Leonid Timashev maintains $COMPASS Pathways(CMPS.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 44.3%
RBC Capital Remains a Buy on COMPASS Pathways (CMPS)
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration